Drugs / RP3
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04735978 | Dec 2020 → Nov 2026 expected | neoplasm | Replimune, Inc. | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05743270 | Jan 2024 → Mar 2026 | head and neck squamous cell carcinoma | Replimune, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT05733611 | Jun 2023 → Aug 2025 | colorectal cancer | Replimune, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05743270 ↗ |
| Route | Other | “intratumoral (IT) injections” NCT04735978 ↗ |